Literature DB >> 31580921

Pre-analytics and tumor heterogeneity.

Serena Bonin1, Giorgio Stanta2.   

Abstract

When dealing with pre-analytics for tissues, it is often that case that tissue heterogeneity, and particularly tumor heterogeneity, is not taken into account as a preliminary condition for obtaining reproducible results in molecular analysis at the diagnostics and clinical research levels. It is well known that when sampling tumor tissues in different areas, for example the border or the central area of the tumor, different genes are expressed and, due to polyclonality in most tumors, different areas can have different DNA and epigenetic alterations. For this reason, it is extremely important to establish and standardize specific tissue sampling protocols for molecular extraction as well as in situ molecular methods. A correct approach to heterogeneity is the basis for a more reproducible and exchangeable type of molecular analysis that can provide useful information at the prognostic and predictive levels. Heterogeneity should also be taken into consideration during cancer treatment, since therapy modifies the clonal composition of tumors. Here, the different types of tumor heterogeneity and the improper pre-analytical conditions in tissue processing that can generate heterogeneous artefacts are described.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical research; Heterogeneity; Intra-tumor heterogeneity; Molecular diagnostics; Pre-analytics; Standardized sampling

Mesh:

Year:  2019        PMID: 31580921     DOI: 10.1016/j.nbt.2019.09.007

Source DB:  PubMed          Journal:  N Biotechnol        ISSN: 1871-6784            Impact factor:   5.079


  5 in total

1.  JP1 suppresses proliferation and metastasis of melanoma through MEK1/2 mediated NEDD4L-SP1-Integrin αvβ3 signaling.

Authors:  Jiahua Cui; Chuanjun Shu; Jin Xu; Dongyin Chen; Jin Li; Kun Ding; Minjuan Chen; Aiping Li; Jingdong He; Yongqian Shu; Liuqing Yang; Ruiwen Zhang; Jianwei Zhou
Journal:  Theranostics       Date:  2020-07-01       Impact factor: 11.556

2.  A Novel HPLC-Based Method to Investigate on RNA after Fixation.

Authors:  Paolo Fattorini; Cristina Forzato; Domenico Tierno; Eleonora De Martino; Eros Azzalini; Vincenzo Canzonieri; Giorgio Stanta; Serena Bonin
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

3.  Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer.

Authors:  Mohamed Bouchahda; Raphael Saffroy; Abdoulaye Karaboué; Jocelyne Hamelin; Pasquale Innominato; Faouzi Saliba; Francis Lévi; Nelly Bosselut; Antoinette Lemoine
Journal:  JCO Precis Oncol       Date:  2020-09-16

4.  Multi-parametric characterization of drug effects on cells.

Authors:  Yael Paran; Yuvalal Liron; Sarit Batsir; Nicola Mabjeesh; Benjamin Geiger; Zvi Kam
Journal:  F1000Res       Date:  2020-10-05

Review 5.  Dynamic Cancer Cell Heterogeneity: Diagnostic and Therapeutic Implications.

Authors:  Valerie Jacquemin; Mathieu Antoine; Geneviève Dom; Vincent Detours; Carine Maenhaut; Jacques E Dumont
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.